14 days | 3 months | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
N | N | |||||||||
A | P | A | P | A-P | A | P | A | P | A-P | |
Mean (SE) Los (days) | 112 | 59 | 11.49 (0.402) | 11.36 (0.577) | 0.14 | 105 | 57 | 43.77 (3.38) | 49.47 (7.28) | -5.7 |
Median (IQR) LoS (days) | 112 | 59 | 14 (9, 14) | 14 (10,14) | 0 | 105 | 57 | 38 (7,84) | 34 (10,84) | 4.0 |
Patients still hospitalised n (%) | 112 | 59 | 76 (67.9) | 38 (64.4) | 3.45% | 105 | 57 | 29 (27.6) | 16 (28.1) | -0.45% |
Study drug consumption, vials. Mean (SE) | 112 | 59 | 4.7 (0.7) | 5.7 (1.1) | -1.02 | 112 | 59 | 4.7 (0.7) | 5.7 (1.1) | -1 |
Study drug consumption, tabs. Mean (SE) | 112 | 59 | 32.53 (2.3) | 45.68 (3.9) | -13.15 | 112 | 59 | 32.5 (2.3) | 45.7 (3.9) | -13.15 |
Cost of hospitalisation, £, mean (SE) | 112 | 59 | 2,548 (71) | 2,525 (101) | 23.78 | 105 | 57 | 8,230 (594) | 9,233 (1282) | -1,003.60 |
Cost of study drugs, £, mean (SE) | 112 | 59 | 4 (1) | 0 (0) | 4.14 | 105 | 59 | 4 (1) | 0 (0) | 4 |
Total cost, £, mean (SE) | 112 | 59 | 2,553 (71) | 2,525 (101) | 27.93 (124) | 105 | 57 | 8,234 (594) | 9,233 (1282) | -999.50 (1413) |